CA
PCRX icon

Clearstead Advisors’s Pacira BioSciences PCRX Stock Holding History

Clearstead Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229 Buy
+9
New +$213 ﹤0.01% 3169
2025
Q4 		– Sell
-295
Closed -$7.6K – 3126
2025
Q3 		$7.6K Hold
295
– – ﹤0.01% 2009
2025
Q2 		$7.05K Buy
+295
New +$7.44K ﹤0.01% 2005

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's PCRX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 9 shares worth $229. The stake represents ﹤0.01% of the portfolio and ranks #3169 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in PCRX as recently as Q3 2025.

Clearstead Advisors first reported a position in PCRX in Q2 2025 and has held it in 3 quarters since. The position peaked at $7.6K in Q3 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Clearstead Advisors held 9 shares of Pacira BioSciences worth $229 as of Q2 2026.
  • Pacira BioSciences was a new Clearstead Advisors position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3169 holding.
  • Clearstead Advisors first reported a position in Pacira BioSciences in Q2 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Pacira BioSciences position peaked at $7.6K in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.